We invite you to visit this page often for the latest company news and resources. If you can't find what you are looking for, please Contact Us for more information. For media and analyst inquiries, please contact Kathleen Fusco at 215-939-5709 or

Press Releases
Two Independent Peer-Reviewed Studies Validate Cernostics’ TissueCypher® Barrett’s Esophagus Assay (TissueCypher®) to Accurately Predict Progression to Esophageal Cancer in Patients with Barrett’s Esophagus... Read More
Cernostics and Deciphex Announce Strategic Collaboration to Develop AI-Based Histology Diagnostics and Prognostics for Barrett’s Esophagus... Read More
Cernostics Announces Blinded, Independent Validation of TissueCypher ® Performance for Predicting Risk of Progression to Esophageal Cancer in Patients with Non-Dysplastic BE... Read More
Media Coverage
Research Validates Tissue Pathology Test Predicting Progression in Barrett’s Esophagus... Read More
Improved Testing for Barrett's Esophagus... Read More
NewCo on the Go: Cernostics aims to help GIs manage Barrett’s patients... Read More
2016 / Medical Laboratory Observer
Individualized risk prediction in Barrett’s esophagus
Barrett’s esophagus (BE), which is a precursor to esophageal adenocarcinoma (EAC), is an increasing healthcare challenge in the United States, but new tools are quickly emerging to combat the uncertainty associated with the disease. Barrett’s esophagus management decisions are often based on sub... Read More
2010 / Springer
Immune Signatures Associated with the Cancer Bearing State
Dysfunction of the host immune system can be detected in many patients with different cancer types, and contributes to tumor escape and failure of therapies that aim to elicit or boost anti-tumor immunity. Yet, immune-mediated tumor rejection and long term cancer control have been documented in a mi... Read More
2011 / Journal of Pathology Informatics
High-throughput profiling of tissue and tissue model microarrays: Combined transmitted light and 3-color fluorescence digital pathology
For many years pathologists have used Hematoxylin and Eosin (H&E), single marker immunohistochemistry (IHC) and in situ hybridization with manual analysis by microscopy or at best simple digital imaging. There is a growing trend to update pathology... Read More
Customer Service

Mon-Fri 9am-5pm (EST)